The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Ensol Biosciences; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Genzyme (Inst)
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis
 
Tao Sun
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Sanja Kostic
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Shusen Wang
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Pfizer
 
Jingfen Wang
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST (Inst); Novartis (Inst)
 
Yong Wha Moon
No Relationships to Disclose
 
Myoung Joo Kang
No Relationships to Disclose
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca
 
Tae-Yong Kim
No Relationships to Disclose
 
Dusan Milenkovic
No Relationships to Disclose
 
Jae Hong Seo
No Relationships to Disclose
 
Jee Hung Kim
Research Funding - Yuhan
 
Ji Eun Lee
No Relationships to Disclose
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)